Genfit
$4.85
83
+$0.12+2.54% Wednesday 20:59
Statistics
Day High
4.93
Day Low
4.37
52W High
5.35
52W Low
2.55
Volume
55,735
Avg. Volume
9,891
Mkt Cap
242.51M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
2AprExpected
Expected EPS
0.01761765
Actual EPS
N/A
Financials
3%Profit Margin
Profitable140.85MRevenue
4.23MNet Income
Analyst Ratings
$7.00Average Price Target
The highest estimate is 7.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow GNFT. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap9.34B
Viking Therapeutics
VKTX
Mkt Cap4.3B
Gilead Sciences
GILD
Mkt Cap148.78B
Agios Pharmaceuticals
AGIO
Mkt Cap2.52B
Galmed Pharmaceuticals
GLMD
Mkt Cap7.51M
FibroGen
FGEN
Mkt Cap44.97M
Axsome Therapeutics
AXSM
Mkt Cap6.74B
About
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Show more...
CEO
Mr. Jean-Francois Mouney
Employees
180
Country
FR
ISIN
US3722791098
Listings
0 Comments
Share your thoughts
FAQ
What is Genfit stock price today?▼
The current price of GNFT is $4.85 USD — it has increased by +2.54% in the past 24 hours. Watch Genfit stock price performance more closely on the chart.
What is Genfit stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Genfit stocks are traded under the ticker GNFT.
Is Genfit stock price growing?▼
GNFT stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Genfit has showed a +25.97% increase.
What is Genfit market cap?▼
Today Genfit has the market capitalization of 242.51M
When is the next Genfit earnings date?▼
Genfit is going to release the next earnings report on April 02, 2026.
What were Genfit earnings last quarter?▼
GNFT earnings for the last quarter are -0.24 USD per share, whereas the estimation was 1.21 USD resulting in a -119.51% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Genfit revenue for the last year?▼
Genfit revenue for the last year amounts to 140.85M USD.
What is Genfit net income for the last year?▼
GNFT net income for the last year is 4.23M USD.
How many employees does Genfit have?▼
As of February 03, 2026, the company has 180 employees.
In which sector is Genfit located?▼
Genfit operates in the Health Care sector.
When did Genfit complete a stock split?▼
Genfit has not had any recent stock splits.
Where is Genfit headquartered?▼
Genfit is headquartered in Loos, FR.